Edwards Lifesciences Q3 2026: Strong Earnings, PASCAL Breakthroughs, and Growing Investor Confidence
Edwards Lifesciences posts Q3 earnings beat with $307.5 M net income, while its PASCAL transcatheter valve shows 80% success in reducing tricuspid regurgitation, boosting investor confidence.
3 minutes to read

